Histological and biomarker landscape of Claudin18.2-positive gastric and gastroesophageal junction cancers: a study of 937 cases
Authors:
- 26 November 2025
- journal article
- research article
- Published by Springer Nature in Virchows Archiv
- Vol. 489 (2) , 1-12
Abstract
Although Claudin18.2 (CLDN18.2) is a promising therapeutic target in gastric and gastroesophageal junction cancer (G/GEJ), its expression profile based on histological subtypes remains unclear. This study aimed to investigate CLDN18.2 expression across various histological subtypes and its associations with clinicopathological features and crucial biomarkers. Tissue sample from 937 patients with G/GEJ was collected. Immunohistochemistry for CLDN18 (43-14A), PD-L1, HER2, and MMR proteins was performed on whole-section slides. EBER was detected by in situ hybridization. The overall positivity rate of CLDN18.2 was 25.8% (242/937). The highest CLDN18.2 positivity rate was observed in adenocarcinoma (AC) at 32.9% (211/641), followed by neuroendocrine neoplasms (NENs) at 12.8% (28/218), with a lower rate in adenosquamous carcinoma (ASC) at 6.3% (3/48), but CLDN18.2 was negative in squamous cell carcinoma (SCC) and undifferentiated carcinoma (P < 0.001). Analysis of AC histomorphology revealed that the highest positivity rate was observed in gastric carcinoma with lymphoid stroma (83.3%), whereas mucinous and hepatoid adenocarcinoma showed lower positivity rates (10.0% and 11.5%, P < 0.001). In ASC, the squamous component demonstrated CLDN18.2 expression in one case, which was characterized by EBV positivity and extensive stromal lymphocytic infiltration. In AC, CLDN18.2 positivity was significantly higher in EBV-positive compared to EBV-negative tumors (70.2% vs. 29.4%, P < 0.001). CLDN18.2 was not significantly associated with PD-L1 or HER2 status regardless of histological subtype (P > 0.05). This study characterized the histological profile of CLDN18.2-positive G/GEJ and broadened our understanding of subgroups likely to benefit from CLDN18.2-targeted therapy.Keywords
Funding Information
- Capital’s Funds for Health Improvement and Research (2024-2-1024)
- Supported by Beijing Natural Science Foundation (7232018)
- National Natural Science Foundation of China (92259302)
This publication has 31 references indexed in Scilit:
- Claudin-18 expression in oesophagogastric adenocarcinomas: a tissue microarray study of 523 molecularly profiled casesBritish Journal of Cancer, 2019
- The origin of p40-negative and CDX2-positive primary squamous cell carcinoma of the stomach: case reportWorld Journal of Surgical Oncology, 2019
- An extremely rare case of Epstein‐Barr virus‐associated gastric carcinoma with differentiation to neuroendocrine carcinomaPathology International, 2017
- Cancer statistics in China, 2015CA: A Cancer Journal for Clinicians, 2016
- Genome‐wide identification of Epstein‐Barr virus–driven promoter methylation profiles of human genes in gastric cancer cellsCancer, 2012
- Host Inflammatory Response Predicts Survival of Patients With Epstein-Barr Virus–Associated Gastric CarcinomaGastroenterology, 2010
- Epstein-Barr Virus-associated Gastric Carcinoma: A Distinct Carcinoma of Gastric Phenotype by Claudin Expression ProfilingJournal of Histochemistry & Cytochemistry, 2009
- Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody DevelopmentClinical Cancer Research, 2008
- Assessment of a HER2 scoring system for gastric cancer: results from a validation studyHistopathology, 2008
- THE TWO HISTOLOGICAL MAIN TYPES OF GASTRIC CARCINOMA: DIFFUSE AND SO‐CALLED INTESTINAL‐TYPE CARCINOMAActa Pathologica Microbiologica Scandinavica, 1965